Publicaciones (38) Publicaciones de FERNANDO ATAULFO GONZÁLEZ FERNÁNDEZ

2024

  1. Largest comparison between onset and relapses of acquired thrombotic thrombocytopenic purpura reveals severe neurological involvement and worse analytic parameters at debut

    Annals of Hematology, Vol. 103, Núm. 3, pp. 725-727

2023

  1. Artificial intelligence to assist specialists in the detection of haematological diseases

    Heliyon, Vol. 9, Núm. 5

  2. Mutations in the RACGAP1 gene cause autosomal recessive congenital dyserythropoietic anemia type III

    Haematologica

  3. Two new mutations in the GLRX5 gene cause sideroblastic anemia

    Blood Cells, Molecules, and Diseases

2022

  1. Does size matter? Two new deletions in the HBB gene cause β0-thalassemia

    Annals of Hematology, Vol. 101, Núm. 7, pp. 1465-1471

  2. Gastrointestinal: Pancytopenia and polyclonal hypergammaglobulinemia in a 52-year-old immunocompromised woman

    Journal of Gastroenterology and Hepatology (Australia), Vol. 37, Núm. 11, pp. 2029

  3. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies

    European Journal of Haematology, Vol. 109, Núm. 3, pp. 205-214

  4. Pincered red cells in hereditary spherocytosis

    Annals of Hematology

  5. β-Thalassemia Intermedia: Interaction of α-Globin Gene Triplication With β-thalassemia Heterozygous in Spain

    Frontiers in Medicine, Vol. 9

2021

  1. Hb Maruchi [α165 (E14) Ala>Pro; HBA1: c.196G>C]: A new thalassemia hemoglobinopathy related to the alpha1 globin gene

    Clinical Biochemistry, Vol. 92, pp. 77-81

  2. Interference of Hemoglobin (Hb) Hope on Measurement of HbA1c Using an HPLC Method

    Journal of Diabetes Science and Technology

  3. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

    European Journal of Haematology, Vol. 106, Núm. 3, pp. 389-397

  4. Sickle cell disease associated with thalassemia; description of a rare mutation

    Clinical Biochemistry, Vol. 94, pp. 80-82

  5. Why is the novel Hb Miguel Servet visualised by CE-HPLC newborn and not by the CE-HPLC β-thalassaemia programme?

    Journal of Clinical Pathology, Vol. 74, Núm. 3, pp. 198-201

2020

  1. Diagnóstico diferencial de las eritrocitosis. Hemoglobinas con alta afinidad por el oxígeno

    Anales de la Real Academia Nacional de Medicina, Núm. 137, pp. 35-43

  2. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

    PLoS ONE, Vol. 15, Núm. 9 September

2019

  1. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study

    Blood, Vol. 133, Núm. 6, pp. 540-549

2018

  1. Clinical and genetic features of congenital dyserythropoietic anemia (CDA)

    European Journal of Haematology, Vol. 101, Núm. 3, pp. 368-378

2017

  1. Hb Moncloa: A new variant of haemoglobin that interferes in the quantification of Hb A1c

    Clinical Biochemistry, Vol. 50, Núm. 9, pp. 521-524

  2. Phenotype of mutations in the promoter region of the β-globin gene

    Journal of Clinical Pathology, Vol. 70, Núm. 10, pp. 874-878